Plant Comparison
Goldenseal vs Mallow
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Goldenseal and Mallow: they share 6 indicated uses (arthritis / joint pain, infection (general), inflammation (general), …); 2 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Goldenseal | Mallow | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 5/10 | 1/10 | Stronger for Goldenseal |
| Infection (general) | 5/10 | 1/10 | Stronger for Goldenseal |
| Inflammation (general) | 5/10 | 2/10 | Stronger for Goldenseal |
| Skin irritation | 5/10 | 2/10 | Stronger for Goldenseal |
| Sore throat | 5/10 | 1/10 | Stronger for Goldenseal |
| Wounds | 5/10 | 5/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Berberine is the main antimicrobial, hypoglycaemic and hypolipidaemic constituent. Notably, whole-leaf extracts are more potent against MRSA than isolated berberine (owing to efflux-pump-inhibitory flavonoids) and show quorum-quenching, anti-virulence activity.
The high mucilage content gives the demulcent, soothing action.
The blue-purple pigments and antioxidant constituents.
Phenolic constituents associated with antioxidant and reported antiproliferative (anticancer) activity in cell studies.
Pharmacological Actions
Anti-inflammatory and astringent for inflamed mucous membranes (sore-throat gargle, mouth)
Antimicrobial (berberine) - supports skin, mucosal and gastrointestinal infections and sore throat
Anti-inflammatory and astringent for inflamed mucous membranes (sore-throat gargle, mouth)
Anti-inflammatory, analgesic and wound-healing (preclinical)
Antibacterial / antimicrobial (methanolic leaf extracts; the naphthoquinone Malvone A)
Demulcent for irritation of the mouth or throat and associated dry cough (soothing mucilage); Mild laxative for occasional constipation (mucilage; traditional)
Mild laxative for occasional constipation (mucilage; traditional)
Traditional & Indicated Uses
inferred from anti-inflammatory action
Digestive / gastrointestinal support (traditional for dyspepsia and ulcers)
Antimicrobial (berberine) - supports skin, mucosal and gastrointestinal infections and sore throat; Topical for skin infections and irritation - whole-leaf extract is active in vitro against methicillin-resistant Staphylococcus aureus (MRSA)
inferred from anti-inflammatory action
inferred from anti-inflammatory action
Anti-inflammatory and astringent for inflamed mucous membranes (sore-throat gargle, mouth); Antimicrobial (berberine) - supports skin, mucosal and gastrointestinal infections and sore throat
inferred from anti-inflammatory action
inferred from anticancer action
Mild laxative for occasional constipation (mucilage; traditional)
Demulcent for irritation of the mouth or throat and associated dry cough (soothing mucilage)
inferred from antimicrobial action
inferred from anti-inflammatory action
inferred from analgesic action
Soothes irritated and inflamed skin and mucous membranes
Safety, Cautions & Contraindications
Contraindicated in pregnancy and breastfeeding: berberine crosses the placenta and into milk and can cause or worsen newborn jaundice (risk of kernicterus); do not give to infants.
Berberine strongly inhibits drug-metabolising enzymes (especially CYP3A4 and CYP2D6), so it can raise the blood levels of many medicines - a significant herb-drug-interaction risk. In a screen of commercial herbal products, goldenseal was among the most potent CYP2D6 inhibitors and also inhibited CYP3A4. High doses have shown possible liver, nerve and photo-toxicity.
Generally very well tolerated. Irritation of the mouth/throat or a cough that persists beyond about a week, or is accompanied by fever or breathlessness, needs medical assessment.
Use in pregnancy and breastfeeding is not recommended in the absence of adequate data.
External Ids
Botanical Description
Low, woodland perennial herb rising from a knotted, bright yellow rhizome with wiry yellow roots. Each stem bears two ragged, palmately lobed, maple-like leaves and a single small, inconspicuous greenish-white flower, followed by a raspberry-like cluster of red berries.[1]
Biennial or short-lived perennial herb, 30-120 cm tall, with erect or sprawling, branched, often reddish stems. Leaves are alternate, long-stalked and palmately lobed with 5-7 shallow rounded lobes and toothed margins. Flowers are pink-purple with darker veining, with five notch-tipped petals borne in small axillary clusters. The fruit is a flattened, disc-shaped schizocarp ('cheese') that splits into a ring of small single-seeded nutlets.[2]
Habitat
Grows in rich, shaded deciduous woodland with humus-rich soil; native to eastern North America, now scarce in the wild due to overharvesting and largely supplied by cultivation.[1]
Common on roadsides, waste ground, hedgebanks and field margins across Europe, North Africa and temperate Asia, and widely naturalised elsewhere; tolerates a wide range of soils, favouring sunny, disturbed, nitrogen-rich sites.[2]
Harvesting
The rhizome and root are dug in autumn from plants at least three to four years old, when berberine content is highest, then cleaned and dried; because wild populations are depleted, cultivated or sustainably sourced material is strongly preferred, and careful identification against the toxic mayapple and bloodroot, which share its woodland habitat, is essential before any wild-harvesting.[1]
Leaves and flowers are gathered during the flowering period (summer) and dried quickly out of direct sun to preserve their mucilage content; fresh material can also be used directly for infusions or poultices.[11]
Traditional Uses
Goldenseal root has a Native American and, after adoption by Eclectic physicians, wider North American tradition as a bitter tonic and antimicrobial remedy for mucous-membrane infections, sore throat, digestive upset and topical skin infections, directly reflecting its high berberine content.[1]
Mallow leaf and flower have a long ethnobotanical history across Europe as a demulcent for irritated mucous membranes - soothing coughs, sore throat and mouth irritation - and for occasional constipation and skin irritation, reflecting the mucilage-rich leaf and flower. Modern phytochemical and pharmacological work confirms antioxidant, anti-inflammatory, antimicrobial and wound-healing activity of its extracts.[2, 11]
Preparations
Dried rhizome and root simmered in water as a traditional bitter antimicrobial tea, or used as a gargle for sore throat.
Tincture 1:10 in 60% ethanol of the dried rhizome and root, 2-4 ml three times daily per the WHO monograph Rhizoma Hydrastis. Educational reference only, not a prescription.
Extract standardised to berberine/hydrastine content, taken as capsules; whole-leaf extracts have shown stronger antimicrobial activity than isolated berberine in some studies.
Dosage
The WHO monograph on Rhizoma Hydrastis gives a daily dose of 0.5-1.0 g of the dried rhizome and root three times, or taken as a decoction; a 1:1 liquid extract in 60% ethanol at 0.3-1.0 mL three times; or a 1:10 tincture in 60% ethanol at 2-4 mL three times. For short-term use only, given goldenseal's potent CYP-enzyme inhibition and its contraindication in pregnancy. Educational reference only, not a prescription.
EMA herbal-monograph guidance suggests roughly 1.5-2 g of dried leaf or flower per cup, taken as an infusion up to 3 times daily. Educational reference only, not a prescription.
References
Drug Class Interactions
Not documented
Lookalikes Review
Dangerous Lookalikes
Not documented
References & Sources
- Mandal, S.K., Maji, A.K., Mishra, S.K., Ishfaq, P.M., Devkota, H.P., Silva, A.S. and Das, N (2020) 'Goldenseal (Hydrastis canadensis L.) and its active constituents: A critical review of their efficacy and toxicological issues', Pharmacological Research. doi:10.1016/j.phrs.2020.105085 Randomized trial
https://doi.org/10.1016/j.phrs.2020.105085 - Corn, J., Tibbitts, D., Ito, H., Schafer, M. and Vasilevsky, N (2021) 'Effects of Hydrastis Canadensis, Commiphora Habessinica, Phytolacca Americana, and Echinacea Purpurea on Bacterial Growth', Alternative Therapies in Health and Medicine, 27(4), pp. 24-27. Preclinical
https://scholar.google.com/scholar?q=Effects%20of%20Hydrastis%20Canadensis%2C%20Commiphora%20Habessinica%2C%20Phytolacca%20Americana%2C%20and%20Echinacea%20Purpurea%20on%20Bacterial%20Growth - Ettefagh, K.A., Burns, J.T., Junio, H.A., Kaatz, G.W. and Cech, N.B (2010) 'Goldenseal (Hydrastis canadensis L.) extracts synergistically enhance the antibacterial activity of berberine via efflux pump inhibition', Planta Medica, 77(8), pp. 835-840. doi:10.1055/s-0030-1250606 Preclinical
https://doi.org/10.1055/s-0030-1250606 - Cech, N.B., Junio, H.A., Ackermann, L.W., Kavanaugh, J.S. and Horswill, A.R (2012) 'Quorum quenching and antimicrobial activity of goldenseal (Hydrastis canadensis) against methicillin-resistant Staphylococcus aureus (MRSA)', Planta Medica, 78(14), pp. 1556--1561. doi:10.1055/s-0032-1315042 Traditional / reference
https://doi.org/10.1055/s-0032-1315042 - Mahady, G.B., Pendland, S.L., Stoia, A. and Chadwick, L.R (2003) 'In vitro susceptibility of Helicobacter pylori to isoquinoline alkaloids from Sanguinaria canadensis and Hydrastis canadensis', Phytotherapy Research, 17(3), pp. 217-221. doi:10.1002/ptr.1108 Preclinical
https://doi.org/10.1002/ptr.1108 - Junio, H.A., Sy-Cordero, A.A., Ettefagh, K.A., Burns, J.T., Micko, K.T., Graf, T.N., Richter, S.J., Cannon, R.E., Oberlies, N.H. and Cech, N.B (2011) 'Synergy-directed fractionation of botanical medicines: a case study with goldenseal (Hydrastis canadensis)', Journal of Natural Products, 74(7), pp. 1621-1629. doi:10.1021/np200336g Preclinical
https://doi.org/10.1021/np200336g - Britton, E.R., Kellogg, J.J., Kvalheim, O.M. and Cech, N.B (2017) 'Biochemometrics to Identify Synergists and Additives from Botanical Medicines: A Case Study with Hydrastis canadensis (Goldenseal)', Journal of Natural Products, 81(3), pp. 484-493. doi:10.1021/acs.jnatprod.7b00654 Preclinical
https://doi.org/10.1021/acs.jnatprod.7b00654 - Leyte-Lugo, M., Britton, E.R., Foil, D.H., Brown, A.R., Todd, D.A., Rivera-Chavez, J., Oberlies, N.H. and Cech, N.B (2017) 'Secondary Metabolites from the Leaves of the Medicinal Plant Goldenseal (Hydrastis canadensis)', Phytochemistry Letters, 20, pp. 54-60. doi:10.1016/j.phytol.2017.03.012 Preclinical
https://doi.org/10.1016/j.phytol.2017.03.012 - Gurley, B.J., Swain, A., Hubbard, M.A., Hartsfield, F., Thaden, J., Williams, D.K., Gentry, W.B. and Tong, Y (2007) 'Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo', Clinical Pharmacology and Therapeutics, 83(1), pp. 61-69. doi:10.1038/sj.clpt.6100222 Randomized trial
https://doi.org/10.1038/sj.clpt.6100222 - Wallace, E.D., Oberlies, N.H., Cech, N.B. and Kellogg, J.J (2018) 'Detection of adulteration in Hydrastis canadensis (goldenseal) dietary supplements via untargeted mass spectrometry-based metabolomics', Food and Chemical Toxicology, 120, pp. 439-447. doi:10.1016/j.fct.2018.07.033 Preclinical
https://doi.org/10.1016/j.fct.2018.07.033 - Douglas, J.A., Follett, J.M., Parmenter, G.A., Sansom, C.E., Perry, N.B. and Littler, R.A (2010) 'Seasonal variation of biomass and bioactive alkaloid content of goldenseal, Hydrastis canadensis', Fitoterapia, 81(7), pp. 925-928. doi:10.1016/j.fitote.2010.06.006 Preclinical
https://doi.org/10.1016/j.fitote.2010.06.006 - Singh, S., Pathak, N., Fatima, E. and Negi, A.S (2021) 'Plant isoquinoline alkaloids: Advances in the chemistry and biology of berberine', European Journal of Medicinal Chemistry. doi:10.1016/j.ejmech.2021.113839 Preclinical
https://doi.org/10.1016/j.ejmech.2021.113839 - World Health Organization (2007) 'Rhizoma Hydrastis'. Available at: https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 Traditional / reference
https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 - Sevior, D.K., Hokkanen, J., Tolonen, A., Abass, K., Tursas, L., Pelkonen, O. and Ahokas, J.T (2010) 'Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail', Xenobiotica, 40(4), pp. 245--254. doi:10.3109/00498251003592683 Preclinical
https://doi.org/10.3109/00498251003592683 - Gurley, B.J., Gardner, S.F., Hubbard, M.A., Williams, D.K., Gentry, W.B., Khan, I.A. and Shah, A (2005) 'In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes', Clinical Pharmacology and Therapeutics, 77(5), pp. 415-426. doi:10.1016/j.clpt.2005.01.009 Randomized trial
https://doi.org/10.1016/j.clpt.2005.01.009 - McDonald, M.G., Tian, D.D., Thummel, K.E., Paine, M.F. and Rettie, A.E (2020) 'Modulation of major human liver microsomal cytochromes P450 by component alkaloids of goldenseal: time-dependent inhibition and allosteric effects', Drug Metabolism and Disposition, 48(10), pp. 1018-1027. doi:10.1124/dmd.120.091041 Preclinical
https://doi.org/10.1124/dmd.120.091041 - Guo, J., Chen, H., Zhang, X., Lou, W., Zhang, P., Qiu, Y., Zhang, C., Wang, Y. and Liu, W.J (2021) 'The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials', Oxidative Medicine and Cellular Longevity, 2021, pp. 2074610. doi:10.1155/2021/2074610 Meta-analysis / review
https://doi.org/10.1155/2021/2074610 - Forest Farming (Cooperative Extension) 'Goldenseal (Hydrastis canadensis L.)'. Available at: https://forest-farming.extension.org/goldenseal-hydrastis-canadensis-l/ Traditional / reference
https://forest-farming.extension.org/goldenseal-hydrastis-canadensis-l/ - Frasca, T. and Brett, A.S. and Yoo, S.D (1997) 'Mandrake toxicity. A case of mistaken identity', Archives of Internal Medicine, 157(17), pp. 2007-9. doi:10.1001/archinte.157.17.2007 Clinical study
https://doi.org/10.1001/archinte.157.17.2007 - North Carolina Extension Gardener Plant Toolbox 'Sanguinaria canadensis (Bloodroot)'. Available at: https://plants.ces.ncsu.edu/plants/sanguinaria-canadensis/ Traditional / reference
https://plants.ces.ncsu.edu/plants/sanguinaria-canadensis/
- Mousavi, S.M., Hashemi, S.A., Behbudi, G., Mazraedoost, S. and others (2021) 'A Review on Health Benefits of Malva sylvestris L. Nutritional Compounds for Metabolites, Antioxidants, and Anti-Inflammatory, Anticancer, and Antimicrobial Applications', Evidence-Based Complementary and Alternative Medicine, 2021, pp. 5548404. doi:10.1155/2021/5548404 Meta-analysis / review
https://doi.org/10.1155/2021/5548404 - Gasparetto, J.C., Martins, C.A., Hayashi, S.S., Otuky, M.F. and others (2012) 'Ethnobotanical and scientific aspects of Malva sylvestris L.: a millennial herbal medicine', Journal of Pharmacy and Pharmacology, 64(2), pp. 172-189. doi:10.1111/j.2042-7158.2011.01383.x Meta-analysis / review
https://doi.org/10.1111/j.2042-7158.2011.01383.x - Wu, Y., Qiu, A., Yang, Z., Wu, J. and others (2019) 'Malva sylvestris extract alleviates the astrogliosis and inflammatory stress in LPS-induced depression mice', Journal of Neuroimmunology, 336, pp. 577029. doi:10.1016/j.jneuroim.2019.577029 Preclinical
https://doi.org/10.1016/j.jneuroim.2019.577029 - Ben Saad, A., Rjeibi, I., Brahmi, D., Smida, A. and others (2016) 'Malva sylvestris extract protects upon lithium carbonate-induced kidney damages in male rat', Biomedicine & Pharmacotherapy, 84, pp. 1099-1107. doi:10.1016/j.biopha.2016.10.026 Preclinical
https://doi.org/10.1016/j.biopha.2016.10.026 - Zuo, H., Li, Y., Cui, Y. and An, Y (2017) 'Cardioprotective effect of Malva sylvestris L. in myocardial ischemic/reperfused rats', Biomedicine & Pharmacotherapy, 95, pp. 679-684. doi:10.1016/j.biopha.2017.08.111 Preclinical
https://doi.org/10.1016/j.biopha.2017.08.111 - Benso, B., Rosalen, P.L., Alencar, S.M. and Murata, R.M (2015) 'Malva sylvestris Inhibits Inflammatory Response in Oral Human Cells. An In Vitro Infection Model', PLoS One, 10(10), pp. e0140331. doi:10.1371/journal.pone.0140331 Preclinical
https://doi.org/10.1371/journal.pone.0140331 - Prudente, A.S., Sponchiado, G., Mendes, D.A.G.B., Soley, B.S. and others (2017) 'Pre-clinical efficacy assessment of Malva sylvestris on chronic skin inflammation', Biomedicine & Pharmacotherapy, 93, pp. 852-860. doi:10.1016/j.biopha.2017.06.083 Preclinical
https://doi.org/10.1016/j.biopha.2017.06.083 - Mohaghegh, Z., Golfakhrabadi, F., Faal Siahkal, S., Dastoorpoor, M. and others (2022) 'The Effect of Malva sylvestris Cream on Episiotomy Pain and Healing: A Randomized Controlled Clinical Trial', International Journal of Community Based Nursing and Midwifery, 10(4), pp. 248-258. doi:10.30476/IJCBNM.2022.95772.2082 Randomized trial
https://doi.org/10.30476/IJCBNM.2022.95772.2082 - Areesanan, A., Nicolay, S., Keller, M., Zimmermann-Klemd, A.M. and others (2023) 'Potential benefits of Malva sylvestris in dry-eye disease pathology in vitro based on antioxidant, wound-healing and anti-inflammatory properties', Biomedicine & Pharmacotherapy, 168, pp. 115782. doi:10.1016/j.biopha.2023.115782 Preclinical
https://doi.org/10.1016/j.biopha.2023.115782 - Martins, C.A., Weffort-Santos, A.M., Gasparetto, J.C., Trindade, A.C. and others (2014) 'Malva sylvestris L. extract suppresses desferrioxamine-induced PGE2 and PGD2 release in differentiated U937 cells', Biomedical Chromatography, 28(7), pp. 986-993. doi:10.1002/bmc.3106 Preclinical
https://doi.org/10.1002/bmc.3106 - European Medicines Agency (HMPC) (n.d.) 'European Union herbal monograph on Malva sylvestris L., folium and flos (Malvae folium / Malvae sylvestris flos)'. Available at: https://www.ema.europa.eu/en/medicines/herbal/malvae-folium Traditional / reference
https://www.ema.europa.eu/en/medicines/herbal/malvae-folium - Paul, Z.A. and Malla, A.T. and Dar, M.A. and Masoodi, M.H (2024) 'Phytochemistry and Pharmacological Activity of Malva sylvestris L.: A Detailed Insight', Combinatorial Chemistry & High Throughput Screening, 27(16), pp. 2309--2322. doi:10.2174/0113862073269336231009110313 Traditional / reference
https://doi.org/10.2174/0113862073269336231009110313 - Batiha, G.E. and Tene, S.T. and Teibo, J.O. and Shaheen, H.M. and Oluwatoba, O.S. and Teibo, T.K.A. and Al-Kuraishy, H.M. and Al-Garbee, A.I. and Alexiou, A. and Papadakis, M (2022) 'The phytochemical profiling, pharmacological activities, and safety of Malva sylvestris: a review', Naunyn-Schmiedeberg's Archives of Pharmacology, 396(3), pp. 421--440. doi:10.1007/s00210-022-02329-w Traditional / reference
https://doi.org/10.1007/s00210-022-02329-w
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.